BACKGROUND AND PURPOSE It has been shown that erythropoietin is neuroprotective in animal models of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). The aim of this study was to determine the safety and feasibility of repetitive high-dose recombinant human erythropoietin (rhEPO) therapy in ALS patients. METHODS Two consecutive studies were conducted. We first recruite...

AIM Postpartum anemia is a common problem in obstetrics. Depending on the severity of anemia, it can cause a wide range of symptoms. Obstetrical management should be focused on avoiding blood transfusion in young and otherwise healthy women. The aim of this study was to examine the effectiveness of recombinant human erythropoietin (rhEPO) combined with iron sucrose compared to iron sucrose alon...

We are writing to comment on the article by Lifshitz L et al. published in Haematologica in June 2010: “Macrophages as novel target cells for erythropoietin”. We read the article with great interest but we have to stress that the Authors have passed over our publications concerning immunomodulatory action of recombinant human erythropoietin (rhEPO) from over the last 12 years. Thus, based on ou...

Erythropoietin (EPO), the principal hematopoietic hormone produced by the kidney and the liver in fetuses, regulates mammalian erythropoiesis and exhibits diverse cellular effects in nonhematopoietic tissues. The introduction of recombinant human EPO (rhEPO) has marked a significant advance in the management of anemia associated with chronic renal failure. At the same time, experimental studies...

recent studies in animal models indicate that recombinant human erythropoietin (rhepo) is very effective in enhancing neurological recovery after spinal cord injury (sci). we aimed to evaluate the effect of rhepo plus methylprednisolone sodium succinate (mpss) compared to mpss alone to improve neurological function of patients after sci in a randomized clinical trial. during a 15-month period 3...

The RP-HPLC method, useful for the separation of a protein of the erythropoietin formulations with different stabilizers, was elaborated. Using this method, rhEPO, HSA and other proteins, can be determined, depending on the sample composition. The method is sensitive and rapid. Our results indicate that this method is useful for quality control of rhEPO in final drug preparations with albumin a...

Allogeneic umbilical cord blood (UCB) has therapeutic potential for cerebral palsy (CP). Concomitant administration of recombinant human erythropoietin (rhEPO) may boost the efficacy of UCB, as it has neurotrophic effects. The objectives of this study were to assess the safety and efficacy of allogeneic UCB potentiated with rhEPO in children with CP. Children with CP were randomly assigned to o...

BACKGROUND Hemodialysis (HD) patients with functional iron deficiency often develop resistance to recombinant human erythropoietin (rhEPO). Recent studies have shown that intravenous ascorbic acid (IVAA) administration could override rhEPO resistance in HD patients. This study was undertaken to test the effects of IVAA in HD patients with normoferritinemic functional iron deficiency accompanied...

Erythropoietin (Epo) treatment has been shown to induce mitochondrial biogenesis in cardiac muscle along with enhanced mitochondrial capacity in mice. We hypothesized that recombinant human Epo (rhEpo) treatment enhances skeletal muscle mitochondrial oxidative phosphorylation (OXPHOS) capacity in humans. In six healthy volunteers rhEpo was administered by sub-cutaneous injection over 8 weeks wi...

BACKGROUND Hemorrhagic shock (HS) is the major leading cause of death after trauma. Up to 50% of early deaths are due to massive hemorrhage. Excessive release of pro-inflammatory cytokine and hypercatecholamine induces hematopoietic progenitor cells (HPCs) apoptosis, leading to multiorgan failure and death. However, still, result remains elusive for hematopoietic stem cells (HSCs) behavior in t...